The discovery that botanical cannabinoids such as delta-9 tetrahydrocannabinol exert some of their effect through binding specific cannabinoid receptor sites has led to the discovery of an endocannabinoid signaling system, which in turn has spurred research into the mechanisms of action and addiction potential of cannabis on the one hand, while opening the possibility of developing novel therapeutic agents on the other. This paper reviews current understanding of CB1, CB2, and other possible cannabinoid receptors, their arachidonic acid derived ligands (e.g. anandamide; 2 arachidonoyl glycerol), and their possible physiological roles. CB1 is heavily represented in the central nervous system, but is found in other tissues as well; CB2 tends to be localized to immune cells. Activation of the endocannabinoid system can result in enhanced or dampened activity in various neural circuits depending on their own state of activation. This suggests that one function of the endocannabinoid system may be to maintain steady state. The therapeutic action of botanical cannabis or of synthetic molecules that are agonists, antagonists, or which may otherwise modify endocannabinoid metabolism and activity indicates they may have promise as neuroprotectants, and may be of value in the treatment of certain types of pain, epilepsy, spasticity, eating disorders, inflammation, and possibly blood pressure control. q
Throughout much of the twentieth century discourse on marijuana was framed principally in sociopolitical terms throughout much of the world, and most especially in the US. The official, governmental point of view in the US, Canada, and Western Europe was that marijuana was an addicting drug devoid of therapeutic benefits. Hence, it was classified as a 'Schedule 1' agent, i.e. a dangerous drug of no medical value.
An opposing view, which gradually gained currency from the 1960 s onward, was that marijuana was a relatively harmless naturally occurring substance. Most users experienced marijuana as having calming, perhaps soporific effects, causing transient memory and other cognitive impairment, and stimulating appetite. While occasional untoward effects were acknowledged (e.g. anxiety reactions; psychotic phenomena), the general view was that any alterations in mood and cognition were transient and that marijuana had little or no addiction potential, at least as evidenced by apparent lack of physiological withdrawal symptoms on its discontinuation.
Gaoni and Mechoulam's [1] characterization of some of marijuana's cannabinoid constituents, and in particular, the identification of delta-9 tetrahydrocannabinol (THC) as the prime psychoactive drug, stimulated laboratory, animal model, and human research; however, whereas, some of the animal studies probed various physiological properties of the cannabinoids, including some that might have therapeutic values, human studies generally concentrated on the addictive and adverse affects of THC and marijuana. 
